Loading company…
Tesseract Medicines develops therapeutics that use cancer-specific intracellular proteins to treat cancer.
Founded in 2022 and based in Newton, US, Tesseract Medicines develops biopharmaceutical treatments for cancer. Its therapeutics are designed to target intracellular proteins specific to cancer. In June 2024, Curie.Bio, Chengwei Capital and Gordian Ventures co-led USD 20 million in seed funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in